Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
September 9, 2011
Affibody AB and GE Healthcare Expands its Relationship in the Field of Large-scale Affinity Purification
STOCKHOLM, Sweden, September 9, 2011 - Affibody AB and GE Healthcare, a division of the General Electric Company, has today expanded its relationship in the field of large-scale affinity...
Read more
August 9, 2011
Interim Report – January to June 2011
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...
May 5, 2011
Interim Report – January to March 2011
May 4, 2011
Algeta ASA obtains licenses to develop cancer therapeutics based on Affibody® technology for two oncology targets
Stockholm May 4, 2011. Affibody AB today signed a license and collaboration agreement with Algeta ASA (OSE: ALGETA) with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on...
March 3, 2011
Year-End Report 2010
Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique...
October 26, 2010
Interim Report – January to September 2010
October 5, 2010
Affibody AB and Amylin Pharmaceuticals, Inc. enter into A License Agreement regarding the Albumod™ platform
Affibody AB and Amylin Pharmaceuticals, Inc. enter into A License Agreement regarding the Albumod™ platform Stockholm, Sweden, October 5, 2010.
September 3, 2010
Interim Report – January to June 2010
April 20, 2010
Interim Report – January to March 2010
